LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

Начало・Списък с акции・Arcus Biosciences Inc

Arcus Biosciences Inc

Отворен

СекторЗдравеопазване

24.84 -5.62

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

24.26

Максимум

26.34

Ключови измерители
By Trading Economics
Приходи	-135M -135M
Продажби	-134M 26M
Марж на печалбата	-519.231
Служители	627
EBITDA	-134M -130M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+10.73% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	1.2B 3.2B
Предишно отваряне	30.46
Предишно затваряне	24.84

Настроения в новините

By Acuity

26%

74%

62 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

8.01 / 8.75 Подкрепа & съпротива

Arcus Biosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.12.2025 г., 23:21 ч. UTC

Печалби

Придобивния, сливания и поглъщания

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3.12.2025 г., 23:14 ч. UTC

Придобивния, сливания и поглъщания

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3.12.2025 г., 22:01 ч. UTC

Значими двигатели на пазара

Costco Wholesale Reports Higher Monthly Sales

3.12.2025 г., 21:38 ч. UTC

Печалби

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3.12.2025 г., 23:59 ч. UTC

Пазарно говорене

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3.12.2025 г., 23:49 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

3.12.2025 г., 23:49 ч. UTC

Пазарно говорене

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3.12.2025 г., 23:49 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3.12.2025 г., 23:13 ч. UTC

Пазарно говорене

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3.12.2025 г., 23:10 ч. UTC

Печалби

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3.12.2025 г., 23:08 ч. UTC

Пазарно говорене

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3.12.2025 г., 23:06 ч. UTC

Придобивния, сливания и поглъщания

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3.12.2025 г., 22:59 ч. UTC

Придобивния, сливания и поглъщания

EQB to Buy PC Financial From Loblaw for About $573.5M

3.12.2025 г., 22:45 ч. UTC

Пазарно говорене

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3.12.2025 г., 22:20 ч. UTC

Печалби

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3.12.2025 г., 22:19 ч. UTC

Печалби

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3.12.2025 г., 22:17 ч. UTC

Печалби

Salesforce Working to Add Voice to Agentforce, CEO Says

3.12.2025 г., 22:16 ч. UTC

Печалби

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3.12.2025 г., 22:15 ч. UTC

Печалби

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3.12.2025 г., 22:10 ч. UTC

Придобивния, сливания и поглъщания

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3.12.2025 г., 22:09 ч. UTC

Придобивния, сливания и поглъщания

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

3.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

3.12.2025 г., 21:49 ч. UTC

Печалби

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3.12.2025 г., 21:23 ч. UTC

Печалби

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3.12.2025 г., 21:19 ч. UTC

Печалби

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3.12.2025 г., 21:06 ч. UTC

Печалби

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3.12.2025 г., 21:04 ч. UTC

Печалби

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3.12.2025 г., 21:04 ч. UTC

Печалби

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3.12.2025 г., 21:03 ч. UTC

Печалби

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Сравнение с други в отрасъла

Ценова промяна

Arcus Biosciences Inc Прогноза

Ценова цел

By TipRanks

10.73% нагоре

12-месечна прогноза

Среден 28.38 USD 10.73%

Висок 56 USD

Нисък 14 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Arcus Biosciences Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

11 ratings

Купи

Задържане

Продай

Според 11 анализатори, дали борсови рейтинги на Arcus Biosciences Inc през последните 3 месеца.

Техническа оценка

By Trading Central

8.01 / 8.75Подкрепа & съпротива

The bullish and bearish events are balanced.

All events are bearish.

Настроение

By Acuity

62 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.